Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing ... antibodies for at least five years within the same field. Oruka Therapeutics is obligated to pay Paragon ...
Healthcare Capital Partners III, L.P. Venrock, a 10% owner of $ORKA, bought 88,794 shares of the company on 02-14-2025 for an estimated $1,015,803. This trade was ...
Another promising candidate, ORKA-002, which targets IL-17A/F ... potential to offer best-in-class treatments in the psoriasis field. Successful go-public transaction, raising over $475 million ...
MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a ...